ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2013
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 5 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- The relationship between metabolic syndrome and increased risk of Barrett's esophagus: an updated systematic review and meta-analysis.BMC gastroenterology · 2020Pooled it
- Abdominal obesity and gastroesophageal cancer risk: systematic review and meta-analysis of prospective studies.Bioscience reports · 2017Pooled it
- Metabolic syndrome is associated with increased risk of Barrett esophagus: A meta-analysis.Medicine · 2016Pooled it
- Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Pooled it
- Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2014Pooled it
- Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Trial
- The feasibility of an exercise intervention in males at risk of oesophageal adenocarcinoma: a randomized controlled trial.PloS one · 2015Trial
- Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis.Signal transduction and targeted therapy · 2026Review
- Causal association between modifiable risk factors and esophageal cancer: A Mendelian randomization study.Discover oncology · 2025Article
- Adiponectin and gastric fundus: A potential target for gut-brain axis dysfunctions.Physiological reports · 2025Review
- Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Nested Case-Control Study in the Department of Defense Serum Repository.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Article
- Translating Molecular Biology Discoveries to Develop Targeted Cancer Interception in Barrett's Esophagus.International journal of molecular sciences · 2023Review
- Global incidence, mortality, and burden of esophageal cancer, and its correlation with SDI, metabolic risks, fasting plasma glucose, LDL cholesterol, and body mass index: An ecological study.Health science reports · 2023Article
- Dietary and Nutritional Support in Gastrointestinal Diseases of the Upper Gastrointestinal Tract (I): Esophagus.Nutrients · 2022Review
- Practical Considerations in Diagnosing and Managing Early-Onset GI Cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Role of Obesity, Physical Exercise, Adipose Tissue-Skeletal Muscle Crosstalk and Molecular Advances in Barrett's Esophagus and Esophageal Adenocarcinoma.International journal of molecular sciences · 2022Review
- Insulin and cancer: a tangled web.The Biochemical journal · 2022Review
- Burden of esophageal cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019.Frontiers in public health · 2022Article
- The tumour immune microenvironment in oesophageal cancer.British journal of cancer · 2021Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsIndividuals with Barrett's esophagus (BE) have an increased risk of developing esophageal adenocarcinoma (EA). Obesity contributes to the development of BE and its progression to cancer. We investigated the roles of obesity-induced hyperinsulinemia and dysregulation of adipokines in these processes.
methodsWe measured fasting levels of glucose, insulin, leptin, and adiponectin in 392 patients enrolled in the Seattle Barrett's Esophagus Study. We calculated homeostatic model assessment scores (a measure of insulin sensitivity) and identified subjects with metabolic syndrome. We evaluated the association between these measures and the risk of EA using Cox regression models adjusted for known risk factors.
resultsIncreasing homeostatic model assessment scores were associated with an increasing risk for EA; the strongest association was observed within the first 3 years after participants entered the study (hazard ratio [HR], 2.45; 95% confidence interval [CI], 1.43-4.1; P trend = .001). Leptin level also was associated significantly with an increased risk of EA within 3 years (HR, 2.51; 95% CI, 1.09-5.81; P trend = .03) and 6 years (HR, 2.07; 95% CI, 1.01-4.26; P trend = .048) of baseline. The level of high-molecular-weight adiponectin had a nonlinear inverse association with risk of EA; the strongest associations were observed in the second tertile (HR, 0.34; 95% CI, 0.14-0.82). Metabolic syndrome was not associated with risk of EA.
conclusionsAmong patients with BE, increased levels of leptin and insulin resistance are associated with increased risk for EA, whereas increased levels of high-molecular-weight adiponectin is associated inversely with EA. These biomarkers might be used to determine cancer risk among patients with BE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.